SITC 2024
Date: Nov 06, 2024
Join us at Booth #933 during the SITC's 39th Annual Meeting in the vibrant city of Houston, TX from November 6-10, 2024.
The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. SITC 2024 also includes updates on major national and international initiatives from academia, government and industry, as well as important society projects.
Poster Presentation
We will present three posters in the poster hall during this meeting.
Abstract Number: 305
Title: Anti-tumor Activity of Chimeric Antigen Receptor T Cells targeting CD19
⇒ Annual Meeting Poster Sessions:
Location: Exhibit Halls A B George R. Brown Convention Center
Dates/Times*: Friday, Nov. 8, 2024 - Odd Number Posters
Abstract Number: 751
Title: huHSC-NKG-ProF Mouse Model: A Reliable Tool for Advancing Tumor Immunology Research
⇒ Immune Engineering Workshop Poster Session:
Location: George R. Brown Convention Center -Level 3 - Grand Ballroom AB
Date/Time*: Thursday, Nov. 7 from 3:10 – 5 p.m.
⇒ Annual Meeting Poster Sessions:
Location: Exhibit Halls A B George R. Brown Convention Center
Dates/Times*: Friday, Nov. 8, 2024 - Odd Number Posters
Abstract Number: 305
Title: Antitumor Activity of GPC3 Chimeric Antigen Receptor Modified NKT Cells
⇒ Annual Meeting Poster Sessions:
Location: Exhibit Halls A B George R. Brown Convention Center
Dates/Times*: Saturday, Nov. 9, 2024 - Even Number Posters
Have questions for our specialists or want more information?
Request a meeting in-person at SITC 2024 to discuss your project.
Click here to book the in-person meeting!
Our booth will feature exciting new developments in the field of gene therapy, and our team will be on hand to answer any questions and share insights. We look forward to seeing you there!
Contact us for a free consultation on your CAM/CGT projects.
Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.
